Cedirogant

N/A

Report date: 2022/12/24 20:00:29

NME

Base Information

Drug NameCedirogant

Drug Alias NameABBV-157ABB-157

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionNuclear receptor ROR-gamma antagonists

TargetsNuclear receptor ROR-gamma

Therapy Area/IndicationsPsoriasisHepatic Insufficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsPsoriasisHepatic Insufficiency

ATC CodeN/A